SLC5A2 and heart failure: In terms of the total hospitalization for heart failure, which included first and recurrent number of hospitalization for heart failure, the result of meta-analysis of four studies (30, 42, 44, 46) demonstrated that SGLT2 inhibitors significantly reduced the total hospitalization for heart failure in patients with HFpEF compared to placebo (RR:0.75, 95% CI: [0.67, 0.84], P<0.00001, I2 = 0%).